Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Abcuro, Inc.

  • Stefano Gulla, Abcuro

Abcuro is developing a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to target key compartments of the immune system.

Abcuro was launched in 2016 and to date it has raised over $10M to advance two functionally differentiated therapeutic programs that target KLRG1, an inhibitory receptor on T and NK cells. Abcuro’s autoimmunity program is under development for inclusion body myositis (IBM), primary biliary cholangitis (PBC) and other T cell driven autoimmunity indications including rare forms of leukemia.

Abcuro's immuno-oncology program is being developed for solid tumors via a biomarker based indication selection strategy.

Both programs have completed candidate selection and are now in pre-clinical development.

  • Date:Monday, February 11
  • Time:11:15 AM - 11:30 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23406
  • Goal for Presentation:Strategy partnership search
  • Company Website:www.abcuro.com
  • Company HQ City:Newton
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$12.25M
  • Year Founded:2016
  • Main Therapeutic Focus:Immunology
  • Lead Product in Development:ABC-015
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
Speakers
Stefano Gulla
Abcuro
Back